Evidence map›Paper›PMID 31616065›Full record

Trial reportBone marrow transplantation2020

A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation.

Zachariah DeFilipp, Shuli Li, David Avigan, Philippe Armand, Vincent T Ho, John Koreth, Sarah Nikiforow, Edwin P Alyea, Jerome Ritz, Vassiliki Boussiotis and 11 more

Open access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 1 country.

Zachariah DeFilippBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7994-8974
Shuli LiDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
David AviganDivision of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Philippe ArmandDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Vincent T HoDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
John KorethDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Sarah NikiforowDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Edwin P AlyeaDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Jerome RitzDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5526-4669
Vassiliki BoussiotisDivision of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3963-1518
Jacalyn RosenblattDivision of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Jami BrownBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
Steven McAfeeBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
Bimalangshu R DeyBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
Areej El-JawahriBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
Thomas R SpitzerBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
Yi-Bin ChenBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9554-1058
Robert J SoifferDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Joseph H AntinDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Karen K Ballen *Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Corey S Cutler *Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA. cscutler@partners.org.
Dana-Farber Cancer Institute · USMassachusetts General Hospital · USBeth Israel Deaconess Medical Center · USUniversity of Virginia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this multicenter Phase 2 single arm study, we substituted low dose total body irradiation (TBI) for antithymocyte globulin (ATG) in a reduced intensity conditioning regimen with the intent to lower the risk for viral infections after double umbilical cord blood (UCB) transplantation. The conditioning regimen consisted of fludarabine (30 mg/m

Indexed as

Cord Blood Stem Cell TransplantationGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansMelphalanTransplantation ConditioningVidarabineWhole-Body IrradiationfludarabineMelphalanVidarabine

Identifiers

PMID31616065
OpenAlexW2981073841

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.